27 C
Vientiane
Monday, November 3, 2025
spot_img
Home Blog Page 901

First Subject Enrolled in Phase 1 Clinical Trial for Luye Pharma’s Investigational Antidepressant Targeting NET/DAT/GABAAR

SHANGHAI, Aug. 3, 2025 /PRNewswire/ — Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China’s Class 1 pathway for innovative drugs. LY03021 is an inhibitor of the norepinephrine transporter (NET), the dopamine transporter (DAT), and a gamma-aminobutyric acid type A receptor-positive allosteric modulator (GABAAR PAM), intended for the treatment of Major Depressive Disorder (MDD).

MDD has a high prevalence rate, a high disability rate, and a high recurrence rate. In China, the lifetime prevalence of this disease is 3.4%, and the 12-month prevalence is 2.1%.[1] Existing antidepressants have failed to deliver satisfactory response and remission rates, their onset of action usually takes 2 to 4 weeks, [2] and patients taking them may have multiple residual symptoms and adverse reactions. Therefore, how to quickly and effectively control the symptoms of MDD and further improve the efficacy of antidepressants and patient prognosis is a challenge in developing such drugs today.

The onset of MDD is believed to be closely associated with imbalances in brain neurotransmitters, including serotonin (5-HT), norepinephrine (NE), dopamine (DA), and gamma-aminobutyric acid (GABA). Among them, GABA has emerged as a key therapeutic target for psychiatric disorders. A series of studies have implied critical roles of the altered GABAergic system, the major inhibitory signaling system of the central nervous system (CNS), in the pathogenesis of MDD.[3] There is also evidence that GABAergic interneurons are involved in depression-related behaviors and rapid antidepressant responses.[4] However, current antidepressants often excessively activate the synaptic GABAA receptor (subtype α1β2γ2), leading to adverse reactions such as excessive sedation, drowsiness, and even confusion. These side effects pose challenges such as a narrow therapeutic window and dose limitations.

Developed on Luye Pharma’s New Chemical Entity/New Therapeutic Entity (NCE/NTE) platform, LY03021 acts on all of the three targets: NET, DAT, and GABAAR, a novel mechanism of action (MoA) that makes it a potential first-in-class antidepressant. By targeting synaptic GABAA receptor (subtype α1β2γ2) and extrasynaptic GABAA receptor (subtype α4β3δ) at a more appropriate binding ratio, this drug enhances the GABAergic activation of GABAA receptors, regulates the glutamate/GABA balance in the brain, inhibits the excessive activation of the hypothalamic-pituitary-adrenal (HPA) axis, and rapidly relieves depressive symptoms. At the same time, it also increases NE and DA levels in the brain by inhibiting NET and DAT, significantly improving core symptoms in addition to anhedonia and sexual dysfunction in MDD patients. Through the wake-promoting effects of NE and DA, it also reduces adverse reactions such as sedation, drowsiness, and loss of consciousness caused by GABA receptor activation.

Non-clinical studies showed that LY03021 significantly inhibited depressive symptoms in animal models 24 hours after administration, and continuous administration could maintain the efficacy until the end of a 21-day study. Apart from its rapid onset of action and sustained efficacy, this drug also has a good safety profile, for its NOAEL (no-observed-adverse-effect-level) is 50 times above its effective dose.

The Phase 1 clinical trial recently initiated in China is a single-center, randomized, double-blind, placebo-controlled, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetic profile of LY03021 in healthy subjects.

There is a huge demand for CNS drugs, including those for treating MDD. However, new drug development in this area has been relatively slow. Luye Pharma has obtained marketing authorizations for a number of internationally competitive innovative drugs and formulations in China, the U.S., Japan, and other markets. Here are some examples: Erzofri® (paliperidone palmitate) extended-release injectable suspension and Rykindo® (risperidone) for extended-release injectable suspension, both approved for marketing in the U.S.; Rivastigmine Twice Weekly Transdermal Patch, which has been approved for marketing in multiple European countries, Japan, and China; and Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets) and Jinyouping® (Rotigotine Microspheres for Injection), both have been approved for marketing in China. In addition, the company is also conducting clinical studies for several other investigational drugs filed through China’s Class 1 pathway, such as LY03020, which targets TAAR1 and 5-HT2CR, LY03015, which targets VMAT2 and Sigma1, and LY03017, which targets 5-HT2AR and 5-HT2CR. 

[1] Yueqin Huang, Yu Wang, Hong Wang, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry.2019 Mar;6(3):211-224.

[2] Guidelines for the Prevention and Treatment of Depressive Disorders in China (2nd Edition). Compiled by the Chinese Society of Psychiatry. Chinese Medical Multimedia Press.

[3] Jiao Zou et al. The efficacy and safety of some new GABAkines for treatment of depression: A systematic review and meta-analysis from randomized controlled trials. Psychiatry Research. Volume 328, October 2023, https://doi.org/10.1016/j.psychres.2023.115450

[4] Manoela V Fogaça et al. Inhibition of GABA interneurons in the mPFC is sufficient and necessary for rapid antidepressant responses. Mol Psychiatry. 2020 Oct 17;26(7):3277–3291. doi: 10.1038/s41380-020-00916-y

 

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to developing, manufacturing, and selling innovative medications. With R&D centers in China, the U.S., and Europe, the company is an international leader in novel drug delivery systems such as microspheres, liposomes, and transdermal patches. It also has multiple innovative products in two categories: new chemical entities and antibodies. From 2021 to 2025, the company has had a total of 13 new drugs approved for marketing, with each of them in one or multiple countries such as the U.S., several European countries, Japan, and China.

The company has 8 manufacturing facilities worldwide, which follow the internationally accepted, GMP-compliant quality management and control systems. To date, the company has launched over 30 products in the central nervous system (CNS), oncology, cardiovascular and other therapeutic areas. It conducts business in over 80 countries and regions, including major pharmaceutical markets such as China, the U.S., Europe, and Japan, and also including fast-growing emerging markets.

 

Laos to Enforce Strict Penalties on Tobacco Companies Failing to Comply with New Graphic Warning Regulations

Samples of the newly graphic on health warnings on cigarette packs

The Lao Ministry of Health is stepping up efforts to reduce smoking by strictly enforcing new rules on cigarette packaging.

“Colorful Guizhou” Shines in Kuala Lumpur – Guizhou Culture and Tourism Promotion Conference Held Successfully in Malaysia


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 3 August 2025 – In an effort to deepen cultural and tourism cooperation between China and Malaysia and further expand into the Southeast Asian market, the Guizhou Culture and Tourism Promotion Conference, hosted by the Department of Culture and Tourism of Guizhou Province, was successfully held in Kuala Lumpur on August 1.

"Colorful Guizhou" Shines in Kuala Lumpur – Guizhou Culture and Tourism Promotion Conference Held Successfully in Malaysia
“Colorful Guizhou” Shines in Kuala Lumpur – Guizhou Culture and Tourism Promotion Conference Held Successfully in Malaysia

The event brought together representatives from Tourism Malaysia, and the Selangor Tourism, leading Malaysian tourism industry stakeholders, and prominent members of the local media. The gathering served as a strong platform to foster future collaboration between Guizhou and Malaysia in the fields of culture and tourism.

In her opening remarks, Ms. Wang Lin, Director of the Publicity and Promotion Division of Guizhou’s Department of Culture and Tourism, delivered a vivid introduction to Guizhou’s diverse tourism offerings. From the majestic Huangguoshu Waterfall, to the emerald landscapes of Xiaoqikong in Libo—dubbed “The Green Jewel on the Earth’s Waistline”, to the intricate silver craftsmanship of the Miao ethnic group, and the ethereal Grand Songs of the Dong people, Guizhou’s natural beauty and cultural richness were on full display.

Ms. Wang also highlighted Guizhou’s popular summer destinations such as “Refreshing Guiyang” and “China’s Cool Capital – Liupanshui”, as well as signature cultural phenomena like the “Village Super League” (Cun Chao) and “Village Basketball Association” (Cun BA). She noted that these grassroots sports events have attracted international attention and reflect the province’s vibrancy and innovative spirit. Ms. Wang expressed strong hopes for increasing tourism exchanges and welcomed more Malaysian visitors to explore Guizhou’s unique charm.

Ms. Wen Weiya, Director of the Guizhou International Mountain Tourism Development Center, introduced the International Mountain Tourism Alliance (IMTA)—a global organization headquartered in Guizhou committed to promoting sustainable mountain tourism development. She showcased mountain-rich regions such as Qianxinan Prefecture, and extended an open invitation to Malaysian tourism professionals to attend the International Mountain and Outdoor Tourism Conference in Guizhou later this year.

Representing the Selangor Tourism, Mr. Mohd Haffez Hanip, Manager of Industry Development, stakeholder and Government Affairs, praised Guizhou’s breathtaking landscapes and cultural depth. “Guizhou’s scenery is truly mesmerizing, offering world-class tourism experiences. Selangor looks forward to forging stronger ties with Guizhou, jointly exploring new market opportunities and advancing the prosperity of both regions’ tourism sectors,” he said.

The conference also featured remarks and discussions from other distinguished guests, including Mr. Khan Keng Yi, Deputy President of the Malaysia-China Folklore Culture Tourism Association, and Datuk Ge Yamei, CEO of Mango Media Malaysia. Participants shared insights on topics such as market collaboration, tourism product development, and cross-border promotional strategies.The Guizhou delegation actively engaged with local travel agencies and media representatives, introducing the province’s tourism highlights, modern transportation infrastructure, and recent cultural-tourism integration efforts. Discussions also explored opportunities for collaboration in areas such as sports tourism (Cun Chao & Cun BA), educational exchange, and tea culture promotion, laying the groundwork for future joint initiatives.

A spokesperson from the Department of Culture and Tourism of Guizhou noted, “This promotional event marks a pivotal moment in strengthening ties between ‘Colorful Guizhou’ and Malaysia’s tourism industry. We value the deepening friendship and the tremendous potential for mutual growth and cooperation.”

As part of its broader Southeast Asia engagement strategy, the Guizhou delegation will continue its outreach efforts at the MITM Travel Fair 2025, held in Kuala Lumpur from August 1–3. Throughout the exhibition, the delegation will showcase the many facets of “Colorful Guizhou” through immersive displays and interactive sessions, extending a warm invitation to Malaysian travelers to experience Guizhou’s cool climate, dramatic landscapes, and rich ethnic heritages.

The issuer is solely responsible for the content of this announcement.

Launch of Global Impact Champions Awards for Financial Health

SINGAPORE, Aug. 2, 2025 /PRNewswire/ — The Global Finance & Technology Network (GFTN) has launched the inaugural Global Impact Champions Awards, with the 2025 theme being Financial Health. These awards spotlight FinTech startups delivering scalable solutions that improve people’s financial lives – helping individuals manage daily needs, build resilience to shocks, plan for a secure future, and feel confident about their finances.

Winning FinTech startups from around the world will be awarded up to US$1 million, subject to terms and conditions. Winners will be presented the awards and invited to speak at the Singapore FinTech Festival (SFF) 2025 in November, attended by a global audience of over 60,000 participants from more than 135 countries. The winners will be informally showcased at the GFTN International Advisory Board (IAB) meeting in The Hague in October.

Financial inclusion is a means to an end. Financial health is the outcome we need, where people can manage daily needs, plan for the future, handle shocks, and feel confident about their financial lives,” Her Majesty Queen Máxima of the Netherlands, United Nations Secretary-General’s Special Advocate for Financial Health and Chair of GFTN IAB, said during the 2024 Singapore FinTech Festival.

Why Financial Health is the Next Step to Financial Inclusion?

“A decade of fintech innovation has shown us that financial inclusion is only the start. What truly matters is financial health – helping people manage daily needs, plan for the future, withstand shocks, and gain confidence in their financial lives. The Global Impact Champions Awards for Financial Health is GFTN’s effort to discover the impact makers – those who not only build systems but also transform lives,” said Sopnendu Mohanty, Group CEO of GFTN.

Awards’ Significance

Financial access is expanding – eight in ten adults now have an account, but access alone does not ensure financial health. In a world shaped by economic volatility, rising debt, and the disruptive effects of AI and automation, too many people remain financially insecure. Only one in three adults globally could cover two months of expenses after an income loss, underscoring the urgent need to strengthen household resilience.

While FinTech innovation has expanded the reach of financial services, real progress depends on improving outcomes and ensuring that people can manage daily needs, navigate uncertainty, and plan for the future with confidence.

The Global Impact Champions Awards for Financial Health aim to accelerate this shift by spotlighting innovators who deliver measurable improvements in people’s financial lives. The awards will recognise FinTech’s potential to move beyond access toward inclusive, AI-enabled solutions that build long-term financial wellbeing, agency and security.

Why Award FinTech Startups?

  • FinTech startups are reimagining financial services to improve people’s financial health, not just expanding access.
  • Many are developing solutions that help users budget, save, build credit safely, plan ahead and manage unexpected shocks.
  • They are leveraging emerging technologies, such as AI, blockchain, and mobile-first platforms, to deliver inclusive, data-driven and user-centric financial tools.
  • Yet despite their promise, startups remain under-recognized in global efforts to strengthen resilience and wellbeing.
  • By awarding FinTech startups, GFTN seeks to accelerate investment and visibility for high-potential ventures delivering tangible, scalable improvements in people’s financial lives.

Dates to Note: 

  • 1 August 2025: Awards open. Click here for the Application form.
  • 7 September 2025, 2359 hours (SGT): Awards submission close.
  • 29 October 2025: Top 3 finalists will be informally showcased at GFTN IAB Meeting at The Hague, the Netherlands.
  • 12 – 14 November 2025: Formal award ceremony at the SFF 2025.

About the Singapore FinTech Festival 2025

The Singapore FinTech Festival (SFF) 2025, organised by the Monetary Authority of Singapore (MAS), Global Finance & Technology Network (GFTN) and Constellar, in collaboration with the Association of Banks in Singapore, will be held from 12 – 14 November 2025, marking its 10th anniversary. This year’s event will focus on celebrating a decade of innovation and collaboration in the FinTech industry, while also addressing critical challenges in global finance to shape the next decade. The Insights Forum will be held from 10 – 11 November 2025.

About GFTN

The Global Finance & Technology Network (GFTN) is a Singapore-headquartered organisation that leverages technology and innovation to create more efficient, resilient, and inclusive financial systems through global collaboration. GFTN hosts a worldwide network of forums (including its flagship event, the Singapore FinTech Festival); advises governments and companies on policies and the development of digital ecosystems and innovation within the financial sector; offers digital infrastructure solutions; and plans to invest in financial technology startups through its upcoming venture fund, with a focus on inclusion and sustainability. GFTN is a not-for-profit organisation established by the MAS in 2024.

For more information on the awards, please visit GFTN Global Impact Champions Awards or contact the Impact Champions Awards Team at impactawards@gftn.com.

Note: The International Advisory Board and the Office of the UNSGSA are not involved in reviewing applications or selecting finalists and will not be informed of applicants or candidate details.

Thai-Cambodian Cyberwarriors Battle on Despite Truce

Cambodia and Thailand: Border dispute intensifies with legal and diplomatic efforts underway.

Lao, Korean Flavors Come Alive at “Thongtaek Tastes of Korea” in Vientiane

Thongtaek Food Festival: The taste of Korea

A three-day cultural food event called “Thongtaek Tastes of Korea” is taking place from 1 to 3 August, at Parkson Shopping Center in Vientiane.

XIXILI Empowers Nursing Mothers with Expert Advice by Ricca Tai


KUALA LUMPUR, MALAYSIA – Media OutReach Newswire – 2 August 2025 – In commemoration of Breastfeeding Week 2025, XIXILI shows its commitment to inclusivity by collaborating with Ricca Tai, a licensed pharmacist with a special focus on mothercare, post-natal wellness, and breastfeeding support, to provide expert breastfeeding advice for mothers.

XIXILI's Award Winning Ultra Soft Pansy Wireless Nursing Bra
XIXILI’s Award Winning Ultra Soft Pansy Wireless Nursing Bra

“Breastfeeding can be both rewarding and challenging, particularly for new mothers learning how to express milk comfortably and effectively,” says XIXILI spokesperson Grace Tan. “It’s a deeply personal journey that requires patience, support, and the right tools to ensure both mother and baby feel nurtured throughout the experience.”

According to Grace, XIXILI remains dedicated to supporting breastfeeding mothers with thoughtfully designed nursing bras that prioritise comfort, functionality, and confidence. This combined initiative with Ricca Tai reflects the brand’s ethos of empowering mothers with products that support their needs during this important stage of life.

Expert Advice For New Mothers

When it comes to breastfeeding, Ricca advises that women obtain an accurate measurement of their nipples to help determine the correct breast shield size, which significantly impacts comfort and milk output. She advises measuring the nipple diameter (excluding the areola) in millimetres after breastfeeding or pumping and adding 2–4 mm to determine the appropriate flange size. A poorly fitted shield may cause discomfort, reduced milk flow, or nipple damage.

The Importance of Nursing Bras & Breast Pumps

Maintaining proper posture can enhance the pumping experience. An upright, well-supported position with relaxed shoulders is recommended. Hands-free pumping bras or dual-function nursing bras can help keep flanges securely in place, reducing arm strain and allowing mothers to focus on other tasks. Ricca further states that techniques such as applying warm compresses, gentle massage, and maintaining skin-to-skin contact with the baby can also support milk let-down.

When selecting a breast pump, she notes that lifestyle requirements should guide the decision. Manual or single electric pumps are suitable for occasional use, whereas double electric or hospital-grade pumps are ideal for regular pumping. For mothers who value discretion and mobility, wearable, hands-free pumps with quiet operation and leak-proof designs are practical options.

XIXILI’s Innovative Designs For Breastfeeding Mothers

The Ultra Soft Pansy Maternity Nursing Bra is designed to offer both comfort and practicality for new mothers. This seamless maternity bra is ideal for wearing at home or on casual days out, providing a wire-free, high-coverage fit.

Crafted with ultra-soft, stretchy knitted fabric, it features removable cup pads for optional shaping and coverage, a breathable centre mesh panel for better ventilation, and a wide, snug elastic band under the bust for lasting comfort. The U-shape back wing, adjustable shoulder straps, and three-panel hook fastening offer reliable support, while easy-access clips allow breastfeeding with just one hand.

By combining thoughtful design with comfort and elegance, XIXILI’s nursing bra and bralette collections are crafted to help mothers feel both supported and confident throughout their breastfeeding journey. The collections are available online and at XIXILI boutiques nationwide. For more information, visit XIXILI’s official website.

Hashtag: #XIXILI




The issuer is solely responsible for the content of this announcement.

XIXILI

A homegrown Malaysian brand, XIXILI offers beautiful fashion lingerie and shapewear in Malaysia that prioritises fit and comfort. With an extensive range of bra sizes from A to I and bands 65 to 110cm, XIXILI caters to women of all shapes and sizes. Expert fitters are dedicated to helping each customer find the perfect bra, boosting confidence and enhancing silhouettes.

XIXILI became the first Malaysian lingerie brand to introduce a Try-On in 3D avatar tool, allowing customers to virtually try on XIXILI lingerie using a 3D avatar tailored to their specific body type and measurements. Whether for everyday wear or something special, XIXILI ensures women always look and feel amazing.

Kepler’s Forerunner K2 “Bumblebee” Robot Completes 8-Hour Livestream at WAIC 2025, signaling major step toward real-world deployment of embodied AI in industrial settings

SHANGHAI, Aug. 2, 2025 /PRNewswire/ — The 2025 World Artificial Intelligence Conference & High-level Meeting on Global AI Governance (WAIC 2025) was held in Shanghai from July 26 to 29, spotlighting cutting-edge AI advancements and governance frameworks. Chinese robotics leader Kepler unveiled an immersive industrial exhibition, featuring its flagship Forerunner K2 “Bumblebee” humanoid robot. The robot successfully completed an 8-hour livestream, demonstrating its technical capabilities and real-world viability across four key application scenarios.


Worlds First: Bipedal Humanoid Robot Completes 8-Hour Endurance Livestream

Endurance limitations have long hindered humanoid robots real-world deployment. On July 27, Keplers Forerunner K2 “Bumblebee” set a new benchmark by completing the industrys first 8-hour nonstop livestream by a bipedal humanoid robot. From 9 AM to 5 PM, the K2 demonstrated its groundbreaking “1-hour charge, 8-hour operation” capability, setting a new endurance standard and solidifying its status as the “ultimate blue-collar robot”.

Standing 175 cm (5 ft 9 in) tall and weighing 75 kg (165 lbs), the 52-degree-of-freedom K2 captivated audiences with dynamic dance routines, blind box retrieval, interactive games (including Pictionary), and precision sorting in simulated industrial settings. 

Zhang Minliang, Hardware Director at Kepler, highlighted the Forerunner K2’s revolutionary actuator system combining planetary roller screw actuators with rotary actuators in a series-parallel configuration. The proprietary design delivers industry-leading endurance and payload capacity. The planetary roller screw actuator uses a unique “planetary transmission + threaded engagement” mechanism that enables high-load, high-precision movement while optimizing energy efficiency – achieving dynamic power savings with near-zero idle consumption.

The 8-hour endurance benchmark was strategically selected to meet real-world industrial demands, balancing technical feasibility with operational requirements. Perfectly aligned with standard logistics and manufacturing shifts, the Forerunner K2’s “1-hour charge, 8-hour endurance” capability enables seamless “9-to-5 plus overtime” workflow integration. This milestone represents the critical trifecta of commercial robotics: scenario adaptability, technological optimization, and economic practicality – ultimately delivering the optimal balance between reliable performance and cost-effective deployment for industrial applications. 

Humanoid Workforce: K2 “Bumblebee” Demonstrates Industrial Versatility at WAIC 2025

At WAIC 2025, Kepler transformed the exhibition floor into four immersive demonstration zones replicating real-world environments: logistics sorting, material handling, automotive manufacturing, and education/research. Four K2 “Bumblebee” humanoids executed precision tasks in each setting, proving their viability as next-generation industrial workforce solutions.

Industrial applications demand both strength and stamina – challenges the K2 Bumblebee overcomes through its advanced roller screw actuator system. Capable of handling 30kg (66 lb) payloads with fluid, coordinated movements, these biomimetic actuators (strategically positioned in thighs, calves and arms) deliver superior load capacity and rigidity versus conventional ball screw systems. The inhouse multi-thread contact design – integrating lead screws, reducers and encoders – enables unmatched performance in high-speed, heavy-duty industrial operations.

Precision is another critical requirement for industrial automation, and Kepler’s K2 “Bumblebee” delivers breakthrough performance. Song Hua, Vice President of Solutions at Kepler, demonstrated the robot’s Nimble Master dexterity system – featuring six-axis force wrists, 11-DoF hands, and 25 force touchpoints per finger. Supported by an integrated rotary mechanism and AI algorithms, the K2 achieves 0.01-degree positioning accuracy and millimeter-level precision. Its human-like reflexive models enable instinctive adjustments – automatically modifying grip strategies when encountering sharp objects or slippery surfaces – ensuring reliable handling of irregularly positioned items. 

The exhibition’s highlight came as the K2 successfully sorted blind box gifts by color and labeling – a task challenging for conventional automation. While traditional systems struggle with soft, deformable packaging, the K2’s purpose-designed micro-models provided real-time tactile and force feedback, enabling flawless execution. This demonstration proved the robot’s superior capability in handling real-world logistics challenges that typically require human intervention. 

The K2 “Bumblebee” achieves fluid motion through its revolutionary tri-component system: embodied perception, embodied decision-making, and embodied execution – mirroring the functional synergy between human brain and cerebellum. Kepler has strategically partnered with China’s leading reasoning-based large language model providers to develop the system’s advanced “brain” capabilities. Complementing this cognitive foundation, the K2’s bionic architecture integrates multiple cameras and sensor arrays, empowered by Kepler’s proprietary precision perception micro-models that enable real-time embodied decision-making. 

Kepler’s engineering breakthrough lies in its specialized micro-models, distilled from larger foundation models while preserving core functionality at dramatically reduced parametric complexity. These task-specific models undergo rigorous training to maximize operational success rates and stability. The K2 currently deploys multi-modal micro-models covering auditory, tactile, force and positional perception. During package handling operations, fingertip tactile sensors provide instantaneous feedback while dedicated force micro-models dynamically calculate perfect grip strength – ensuring secure manipulation of diverse objects. 

Kepler Launches Pre-Sales for K2 “Bumblebee”, Marking Major Commercialization Milestone

Kepler’s hardware-centric development strategy focuses on vertically integrated core technologies, including custom-built planetary roller screw actuators and the Nimble Master dexterity system, developed through strategic partnerships with leading manufacturers to create a comprehensive technology-to-market ecosystem. 

True to its mission of transforming industrial productivity through robotic workforce solutions, Kepler has successfully validated the K2 “Bumblebee” in real-world applications with multiple industry partners. The platform has demonstrated operational excellence in diverse scenarios, including logistics and warehouse operations (handling/sorting), manufacturing processes (stamping/feeding), education and research applications, and customer-facing roles (exhibition reception).

As the K2 “Bumblebee” enters mass production, Kepler is committed to developing region-specific application solutions tailored to local industrial standards and operational requirements. The company invites strategic partnerships across industries to co-create value and maximize the potential of humanoid robotics in real-world applications. 

Marking a historic milestone, Kepler has officially opened pre-sales for its K2 “Bumblebee” – the world’s first commercially available planetary roller screw-driven humanoid robot. The product lineup features three configurations: Bipedal Basic, Bipedal Developer and Wheeled Developer (starting at ¥248,000). Early adopters purchasing through official channels will benefit from an exclusive 10x multiplier incentive program. The launch represents Kepler’s successful transition from R&D to commercialization, paving the way for widespread adoption of embodied intelligence across global industries. 

Kepler Charts Future Path: Redefining Industries Through Hardware Innovation

The rise of intelligent robotics has ushered in unprecedented opportunities, with embodied intelligence standing at the forefront of technological advancement. Kepler remains steadfast in its “hardware-first” approach, recognizing that conventional industrial and consumer-grade components fall short of meeting humanoid robots’ demanding requirements for compact size, extreme durability, and seamless system integration. Rather than awaiting supply chain evolution, Kepler is partnering with leading publicly traded manufacturers to co-develop and validate mission-critical components – including next-generation joint modules – creating a world-class development and supply alliance for humanoid robotics. 

While maintaining hardware leadership, Kepler is simultaneously evolving its robots’ cognitive capabilities (“brain”) and motion intelligence (“cerebellum”). The commercialization of embodied AI presents formidable challenges, yet Kepler’s global expansion blueprint is strategically designed to bring Chinese humanoid robots from conceptual design to real-world application. The company is establishing new industry standards across three critical areas: usability in diverse operational environments, manufacturability at commercial scale, and practical deployment across industries. As the vanguard of this transformation, Kepler’s breakthroughs are positioned to revolutionize global production systems and redefine daily life through advanced embodied intelligence solutions.